|
市場調査レポート
商品コード
1729260
日本のヘパリン市場レポート：製別品、ソース別、投与方法別、用途別、エンドユーザー別、流通チャネル別、地域別、2025年～2033年Japan Heparin Market Report by Product, Source, Mode of Administration, Application, End User, Distribution Channel, and Region 2025-2033 |
||||||
カスタマイズ可能
|
|||||||
| 日本のヘパリン市場レポート：製別品、ソース別、投与方法別、用途別、エンドユーザー別、流通チャネル別、地域別、2025年～2033年 |
|
出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 121 Pages
納期: 5～7営業日
|
- 全表示
- 概要
- 目次
日本のヘパリンの市場規模は2024年に3億3,750万米ドルに達しました。今後、IMARC Groupは、市場は2033年までに6億900万米ドルに達し、2025年から2033年の間に6.27%の成長率（CAGR）を示すと予測しています。深部静脈血栓症、肺塞栓症、心房細動など、抗凝固療法を必要とする心血管疾患の増加が市場を牽引しています。
本レポートで扱う主な質問
- 日本のヘパリン市場はこれまでどのように推移し、今後どのように推移していくのか？
- 日本のヘパリン市場にCOVID-19が与えた影響は？
- 日本のヘパリン市場の製品別区分は？
- 日本のヘパリン市場のソース別区分は？
- 日本のヘパリン市場の投与方別区分は？
- 日本のヘパリン市場の用途別区分は？
- 日本のヘパリン市場のエンドユーザー別区分は？
- 日本のヘパリン市場の流通チャネル別区分は？
- 日本のヘパリン市場のバリューチェーンにおける様々なステージとは？
- 日本のヘパリンの主な促進要因と課題は？
- 日本のヘパリン市場の構造と主要企業は？
- 日本のヘパリン市場における競合の程度は？
目次
第1章 序文
第2章 調査範囲と調査手法
- 調査の目的
- ステークホルダー
- データソース
- 市場推定
- 調査手法
第3章 エグゼクティブサマリー
第4章 日本のヘパリン市場-イントロダクション
- 概要
- 市場力学
- 業界動向
- 競合情報
第5章 日本のヘパリン市場情勢
- 過去と現在の市場動向（2019年～2024年）
- 市場予測（2025年～2033年）
第6章 日本のヘパリン市場：製品別の内訳
- 未分画ヘパリン
- 低分子量ヘパリン（LMWH）
- 超低分子量ヘパリン（ULMWH）
第7章 日本のヘパリン市場：ソース別の内訳
- 牛
- 豚
第8章 日本のヘパリン市場：投与方法別の内訳
- 経口
- 非経口
第9章 日本のヘパリン市場：用途別の内訳
- 心房細動・心臓発作
- 脳卒中
- 深部静脈血栓症（DVT）
- 肺塞栓症（PE）
- その他
第10章 日本のヘパリン市場：エンドユーザー別の内訳
- 病院
- クリニック
- 在宅医療
- 外来手術センター
- その他
第11章 日本のヘパリン市場：流通チャネル別の内訳
- 病院薬局
- 小売薬局
- ドラッグストア
- オンラインストア
- その他
第12章 日本のヘパリン市場：競合情勢
- 概要
- 市場構造
- 市場企業のポジショニング
- 主要成功戦略
- 競合ダッシュボード
- 企業評価象限
第13章 主要企業のプロファイル
第14章 日本のヘパリン市場：業界分析
- 促進要因、抑制要因、機会
- ポーターのファイブフォース分析
- バリューチェーン分析
第15章 付録
Japan heparin market size reached USD 337.5 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 609.0 Million by 2033, exhibiting a growth rate (CAGR) of 6.27% during 2025-2033. The increasing cases of cardiovascular diseases such as deep vein thrombosis, pulmonary embolism, atrial fibrillation, etc., that require anticoagulant therapy, are driving the market.
Heparin is a widely used anticoagulant medication that helps in preventing the production of blood clots in the circulatory system. It is a naturally occurring substance found in the liver and mast cells of animals, particularly in the mucous membranes of the lungs and intestines. Heparin works by inhibiting the activity of thrombin and other clotting factors, thereby preventing the conversion of fibrinogen into fibrin, a crucial step in blood clot formation. Heparin is administered through intravenous or subcutaneous injection and is commonly employed in various medical settings, including surgeries, dialysis, and as a treatment for ailments, such as pulmonary embolism and deep vein thrombosis. It is considered a fast-acting anticoagulant and is often used in emergency situations to prevent life-threatening clots. However, its use requires careful monitoring to avoid excessive bleeding, and patients may need frequent blood tests to adjust the dosage.
Japan Heparin Market Trends:
Numerous key factors are driving the growth of the heparin market in Japan. Firstly, an aging regional population is contributing to increased demand for heparin-based therapies, as older individuals are more susceptible to conditions like deep vein thrombosis and pulmonary embolism. Additionally, the rising cases of chronic diseases such as cardiovascular disorders and cancer are bolstering the need for anticoagulant treatments like heparin. Furthermore, the rising importance of anticoagulants in managing severe cases is also creating a positive outlook for the market. Moreover, the pharmaceutical industry's ongoing R&D efforts are yielding novel formulations and delivery methods for heparin, enhancing its effectiveness and safety profile. Regulatory agencies are also playing a pivotal role in driving the market by enforcing stringent quality standards and safety regulations, which inspire confidence among healthcare professionals and patients alike. Furthermore, the escalating awareness about the benefits of heparin and its growing availability in emerging markets are fueling market expansion. Lastly, numerous advancements in medical technology and surgical procedures, which have expanded the applications of heparin, promoting its adoption in various medical settings, are expected to drive the heparin market in Japan in the coming years.
Japan Heparin Market Segmentation:
Product Insights:
- Unfractionated Heparin
- Low Molecular Weight Heparin (LMWH)
- Ultra-Low Molecular Weight Heparin (ULMWH)
Source Insights:
- Bovine
- Porcine
Mode of Administration Insights:
- Oral
- Parenteral
Application Insights:
- Atrial Fibrillation and Heart Attack
- Stroke
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Others
End User Insights:
- Hospitals
- Clinics
- Homecare Settings
- Ambulatory Surgical Centers
- Others
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Stores
- Others
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Key Questions Answered in This Report:
- How has the Japan heparin market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the Japan heparin market?
- What is the breakup of the Japan heparin market on the basis of product?
- What is the breakup of the Japan heparin market on the basis of source?
- What is the breakup of the Japan heparin market on the basis of mode of administration?
- What is the breakup of the Japan heparin market on the basis of application?
- What is the breakup of the Japan heparin market on the basis of end user?
- What is the breakup of the Japan heparin market on the basis of distribution channel?
- What are the various stages in the value chain of the Japan heparin market?
- What are the key driving factors and challenges in the Japan heparin?
- What is the structure of the Japan heparin market and who are the key players?
- What is the degree of competition in the Japan heparin market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Japan Heparin Market - Introduction
- 4.1 Overview
- 4.2 Market Dynamics
- 4.3 Industry Trends
- 4.4 Competitive Intelligence
5 Japan Heparin Market Landscape
- 5.1 Historical and Current Market Trends (2019-2024)
- 5.2 Market Forecast (2025-2033)
6 Japan Heparin Market - Breakup by Product
- 6.1 Unfractionated Heparin
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
- 6.2 Low Molecular Weight Heparin (LMWH)
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
- 6.3 Ultra-Low Molecular Weight Heparin (ULMWH)
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
7 Japan Heparin Market - Breakup by Source
- 7.1 Bovine
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
- 7.2 Porcine
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
8 Japan Heparin Market - Breakup by Mode of Administration
- 8.1 Oral
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
- 8.2 Parenteral
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
9 Japan Heparin Market - Breakup by Application
- 9.1 Atrial Fibrillation and Heart Attack
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
- 9.2 Stroke
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
- 9.3 Deep Vein Thrombosis (DVT)
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
- 9.4 Pulmonary Embolism (PE)
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2019-2024)
- 9.4.3 Market Forecast (2025-2033)
- 9.5 Others
- 9.5.1 Historical and Current Market Trends (2019-2024)
- 9.5.2 Market Forecast (2025-2033)
10 Japan Heparin Market - Breakup by End User
- 10.1 Hospitals
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2019-2024)
- 10.1.3 Market Forecast (2025-2033)
- 10.2 Clinics
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2019-2024)
- 10.2.3 Market Forecast (2025-2033)
- 10.3 Homecare Settings
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2019-2024)
- 10.3.3 Market Forecast (2025-2033)
- 10.4 Ambulatory Surgical Centers
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2019-2024)
- 10.4.3 Market Forecast (2025-2033)
- 10.5 Others
- 10.5.1 Historical and Current Market Trends (2019-2024)
- 10.5.2 Market Forecast (2025-2033)
11 Japan Heparin Market - Breakup by Distribution Channel
- 11.1 Hospital Pharmacies
- 11.1.1 Overview
- 11.1.2 Historical and Current Market Trends (2019-2024)
- 11.1.3 Market Forecast (2025-2033)
- 11.2 Retail Pharmacies
- 11.2.1 Overview
- 11.2.2 Historical and Current Market Trends (2019-2024)
- 11.2.3 Market Forecast (2025-2033)
- 11.3 Drug Stores
- 11.3.1 Overview
- 11.3.2 Historical and Current Market Trends (2019-2024)
- 11.3.3 Market Forecast (2025-2033)
- 11.4 Online Stores
- 11.4.1 Overview
- 11.4.2 Historical and Current Market Trends (2019-2024)
- 11.4.3 Market Forecast (2025-2033)
- 11.5 Others
- 11.5.1 Historical and Current Market Trends (2019-2024)
- 11.5.2 Market Forecast (2025-2033)
12 Japan Heparin Market - Competitive Landscape
- 12.1 Overview
- 12.2 Market Structure
- 12.3 Market Player Positioning
- 12.4 Top Winning Strategies
- 12.5 Competitive Dashboard
- 12.6 Company Evaluation Quadrant
13 Profiles of Key Players
- 13.1 Company A
- 13.1.1 Business Overview
- 13.1.2 Product Portfolio
- 13.1.3 Business Strategies
- 13.1.4 SWOT Analysis
- 13.1.5 Major News and Events
- 13.2 Company B
- 13.2.1 Business Overview
- 13.2.2 Product Portfolio
- 13.2.3 Business Strategies
- 13.2.4 SWOT Analysis
- 13.2.5 Major News and Events
- 13.3 Company C
- 13.3.1 Business Overview
- 13.3.2 Product Portfolio
- 13.3.3 Business Strategies
- 13.3.4 SWOT Analysis
- 13.3.5 Major News and Events
- 13.4 Company D
- 13.4.1 Business Overview
- 13.4.2 Product Portfolio
- 13.4.3 Business Strategies
- 13.4.4 SWOT Analysis
- 13.4.5 Major News and Events
- 13.5 Company E
- 13.5.1 Business Overview
- 13.5.2 Product Portfolio
- 13.5.3 Business Strategies
- 13.5.4 SWOT Analysis
- 13.5.5 Major News and Events
14 Japan Heparin Market - Industry Analysis
- 14.1 Drivers, Restraints and Opportunities
- 14.1.1 Overview
- 14.1.2 Drivers
- 14.1.3 Restraints
- 14.1.4 Opportunities
- 14.2 Porters Five Forces Analysis
- 14.2.1 Overview
- 14.2.2 Bargaining Power of Buyers
- 14.2.3 Bargaining Power of Suppliers
- 14.2.4 Degree of Competition
- 14.2.5 Threat of New Entrants
- 14.2.6 Threat of Substitutes
- 14.3 Value Chain Analysis
